Filing Flows › Xilio Therapeutics (XLO) › R&D spending
Xilio Therapeutics (XLO) R&D spending by quarter
Xilio Therapeutics' R&D spending was $14.6M in Q2 2026 (second quarter 2026), -27% from Q1 2026. Over the last 7 quarters it ranged from $8.3M (Q1 2025) to $19.8M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $14.6M | -27% | -5% |
| Q1 2026 | $19.8M | +9% | +140% |
| Q4 2025 | $18.1M | +27% | +105% |
| Q3 2025 | $14.3M | -7% | — |
| Q2 2025 | $15.3M | +85% | — |
| Q1 2025 | $8.3M | -6% | — |
| Q4 2024 | $8.8M | — | — |
Q2 2026 at a glance
Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%, net loss $6.4M, operating cash flow −$18.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is Xilio Therapeutics' R&D spending?
Xilio Therapeutics' R&D spending was $14.6M in Q2 2026 (second quarter 2026), -27% from Q1 2026.
How has Xilio Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $8.3M (Q1 2025) to $19.8M (Q1 2026).